Literature DB >> 30072374

Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.

Merve Hasanov1, Sergej N Konoplev2, Cristhiam M Rojas Hernandez3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30072374      PMCID： PMC6093738          DOI： 10.1182/bloodadvances.2018019000

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.

Authors:  Clément Deltombe; Claire Garandeau; Karine Renaudin; Maryvonne Hourmant
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

2.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Authors:  Padmanee Sharma; Margitta Retz; Arlene Siefker-Radtke; Ari Baron; Andrea Necchi; Jens Bedke; Elizabeth R Plimack; Daniel Vaena; Marc-Oliver Grimm; Sergio Bracarda; José Ángel Arranz; Sumanta Pal; Chikara Ohyama; Abdel Saci; Xiaotao Qu; Alexandre Lambert; Suba Krishnan; Alex Azrilevich; Matthew D Galsky
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316

3.  Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.

Authors:  Magalie P Tardy; Lauris Gastaud; Annick Boscagli; Frederic Peyrade; Andrea Gallamini; Antoine Thyss
Journal:  Hematol Oncol       Date:  2016-08-19       Impact factor: 5.271

Review 4.  Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.

Authors:  Sigbjørn Berentsen; Geir E Tjønnfjord
Journal:  Blood Rev       Date:  2012-02-12       Impact factor: 8.250

Review 5.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.

Authors:  Drew Provan; Tom Butler; Maria Laura Evangelista; Sergio Amadori; Adrian C Newland; Roberto Stasi
Journal:  Haematologica       Date:  2007-12       Impact factor: 9.941

7.  Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.

Authors:  Peng-Fei Wang; Yang Chen; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Front Pharmacol       Date:  2017-10-18       Impact factor: 5.810

8.  Immunotherapy-associated autoimmune hemolytic anemia.

Authors:  Uqba Khan; Farman Ali; Muhammad Siddique Khurram; Awais Zaka; Tarik Hadid
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

9.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316

10.  Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia.

Authors:  K S Schwab; A Heine; T Weimann; G Kristiansen; P Brossart
Journal:  Case Rep Oncol       Date:  2016-06-27
View more
  3 in total

1.  Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Authors:  Rebecca Karp Leaf; Christopher Ferreri; Deepa Rangachari; James Mier; Wesley Witteles; George Ansstas; Theodora Anagnostou; Leyre Zubiri; Zofia Piotrowska; Thein H Oo; David Iberri; Mark Yarchoan; April K S Salama; Douglas B Johnson; Andrew D Leavitt; Osama E Rahma; Kerry L Reynolds; David E Leaf
Journal:  Am J Hematol       Date:  2019-03-13       Impact factor: 13.265

2.  Pembrolizumab-Induced Cold Agglutinin Disease.

Authors:  Osman Atiq; Saad O Atiq; Zainab O Atiq; Vijay Patel; Mohammad O Atiq; Omar T Atiq
Journal:  Am J Case Rep       Date:  2020-09-05

3.  Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.

Authors:  Atsushi Isoda; Yuri Miyazawa; Kenichi Tahara; Masahiro Mihara; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.